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Objective: The purpose of this study was to review the initial results of carotid artery angioplasty with stenting (CAS)
performed by vascular surgeons to treat bifurcation occlusive disease. Most patients were selected for CAS if they had
indications for endarterectomy (CEA) but were considered at high risk for surgery.
Methods: Since December 2000, 74 carotid arteries in 69 patients underwent CAS, with distal balloon embolization
protection in 96%. Mean patient age was 72 years; 82% of patients were men. Indications for CAS included asymptomatic
disease (62%), transient ischemic attack (TIA; 23%), and cerebrovascular accident (15%). Mean internal carotid artery
diameter stenosis was 82%. CAS was chosen over CEA because of cardiac (49%) or pulmonary (4%) comorbid conditions,
hostile neck (25%), distal extent of disease (6%), and contralateral cranial nerve injury (1%). CAS was performed in 15%
patients who were good surgical candidates, because of patient preference. Pathologic conditions were primary athero-
sclerosis (81%), recurrent carotid stenosis (18%), and dissection (1%). Procedures were transfemoral in 95% of cases and
transcarotid in 5%. In 30% of cases the contralateral carotid artery had 80% or greater stenosis or was completely occluded.
Results: Technical success was achieved in 96% of cases. There were no deaths, no major strokes, one minor stroke
(National Institutes of Health Stroke Scale, 3), and one TIA (neurologic event rate, 2.6%). The single minor stroke
resolved completely by 1 month. One patient (1.3%) had a perioperative myocardial infarction. Transient neurologic
changes occurred in 8% of patients during the protection balloon inflation, and all resolved with deflation. Bradyarrhyth-
mia requiring pharmacologic treatment occurred in 14% of patients. At mean follow-up of 6 months there have been two
instances of recurrent stenosis greater than 50% as noted at duplex scanning. During the same period, 266 carotid CEAs
were performed, with a neurologic event rate of 0.8% (major stroke, 0.4%; no minor strokes; TIA, 0.4%) and a myocardial
infarction rate of 3%. Combined stroke and death rate was 1.3% in patients who underwent CAS and 0.5% in patients who
underwent CEA.
Conclusion: CAS with cerebral protection can be performed safely in patients at high surgical risk, with low perioperative
morbidity and mortality. The durability of the procedure must be determined with longer follow-up. (J Vasc Surg 2004;
39:1193-9.)Carotid endarterectomy (CEA) has been used to suc-
cessfully treat extracranial carotid bifurcation occlusive dis-
ease for more than four decades. Randomized multicenter
clinical trials have demonstrated the effectiveness of CEA in
selected patients with both symptomatic and asymptomatic
carotid stenosis.1-6 Carotid artery angioplasty with stenting
(CAS) to treat extracranial carotid occlusive disease has
slowly evolved as a possible alternative therapy that may be
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The Stenting and Angioplasty with Protection in Pa-
tients at High Risk for Endarterectomy trial (SAPPHIRE),
a multicenter randomized trial comparing CAS with CEA
in patients at high surgical risk with symptomatic and
asymptomatic disease with severe extracranial carotid ste-
nosis demonstrated a 5.8% combined stroke, myocardial
infarction, and death rate, compared with a 12.5% rate in
the CEA group.7,8 This is the first study to suggest that
CAS may have a better outcome than CEA in selected
patients. The role of CAS in the treatment of extracranial
carotid occlusive disease remains unclear. At least initially,
this procedure seems best suited in patients who are at high
risk for CEA. Two groups of patients have been considered
at increased risk for CEA: patients with anatomic chal-
lenges, such as previous carotid surgery, neck dissection,
and lesions that extend above the level of the C2 vertebral
body; and patients with significant associated medical co-
morbid conditions, such as unreconstructed coronary ar-
tery disease, congestive heart failure, and recent myocardial
infarction.1193
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deemed at increased risk for complications after CEA. This
includes all patients to date who have undergone CAS
performed by vascular surgeons, including patients who
would be included in the “learning curve.” We also focus
on the use of embolization protection during CAS.
METHODS
Data for all patients who underwent CAS to treat
extracranial carotid bifurcation occlusive disease from De-
cember 2000 through September 2003 were reviewed.
Patients who had stent-graft placement because of trauma
(n  3), stents placed at the time of CEA because of distal
flap (n 4), or combined coronary bypass and CAS (n 1)
were excluded. Data were prospectively entered into a
database. The study was not carried out under a research
protocol, but the risks and benefits of CAS compared with
CEA were reviewed in detail with each patient before
proceeding with CAS, and this review was approved by the
institutional review board.
For purposes of this review, patients at high risk were
classified as having either anatomic high risk or medical
high risk. Anatomic high risk included previous carotid
surgery, neck dissection, radiation therapy to the neck,
lesions extending above the C2 vertebral body, presence of
a stoma, and contralateral cranial nerve injury. Medical high
risk included cardiac comorbidity, such as myocardial in-
farction or congestive heart failure within 3 months or
unreconstructed coronary artery disease; and pulmonary
comorbidity, such as need for home use of oxygen. Initially
only patients at high risk were offered CAS; later in this
experience, some patients at normal risk were offered CAS
if this was their distinct preference.
Patients received either clopidogrel, 75 mg/d for 1
week, or a single 300-mg loading dose of clopidogrel orally
on the morning of the procedure. In addition, patients
were given oral aspirin throughout the perioperative pe-
riod. Procedures were performed either in the operating
room, with an OEC 9800 portable C-arm with 12-inch
image intensifier (OEC Medical Systems, Salt Lake City,
UT) and four-way floating carbon fiber table, or in a
radiology suite, with a fixed GE system (GE Medical Sys-
tems, Milwaukee, Wis) with a 16-inch image intensifier. An
anesthesiologist was present throughout the procedure.
Procedures were performed with the patient under local
anesthesia, with minimal or no conscious sedation, and an
arterial catheter for monitoring blood pressure.
Thoracic arch aortography was performed via a femoral
approach. Patients received 3000 to 5000 units of heparin
intravenously during the diagnostic portion of the proce-
dure. In most cases only the ipsilateral carotid artery was
studied, since patients were selected on the basis of preop-
erative duplex scans. First a 6F shuttle sheath (90 cm long;
Cook, Chicago, Ill) was placed into the distal aortic arch.
Either a 125-cm Vitek catheter (Cook) or vertebral cathe-
ter (Cook) and an exchange-length stiff guide wire (Glide-
wire, Terumo; Boston Scientific, Natick, Mass) were used
to canulate the appropriate common carotid artery. A roadmap arteriographic image of the carotid bifurcation was
then obtained. With use of the road map image, the stiff
guide wire was advanced into the external carotid artery and
advanced into the third-order branches. The diagnostic
catheter and 6F shuttle sheath were then advanced coaxially
into the mid–common carotid artery below the carotid
bifurcation. Adequate heparin was given to elevate acti-
vated clotting time to 300 seconds. Ipsilateral intracranial
arteriograms in lateral and AP views were obtained. The
lesion was then crossed with a 200-cm long PercuSurge
GuardWire antiembolization device (Medtronic/AVE,
Sunnyvale, Calif), which was positioned 3 cm beyond the
stenosis in a straight portion of the internal carotid artery
(ICA). In all cases the PercuSurge device crossed the lesion
without the need for predilation. The GuardWire balloon
was serially inflated as described by the manufacturer, from
4 mm to 6 mm in diameter, until flow was occluded
through the ICA, as determined at arteriography. Once
flow was occluded through the ICA and no neurologic
deficit developed, the lesion was predilated with a 3-mm
rapid-exchange balloon (Gazelle; Boston Scientific). Based
on the GuardWire balloon diameter required to occlude
the ICA, either an 8-mm or 10-mm rapid-exchange Wall-
Stent (Boston Scientific) was placed across the lesion and
dilated with either a 5-mm or 6-mm balloon (Gazelle;
Boston Scientific). The aspiration catheter was then placed
over the wire, and the ICA proximal to the GuardWire
balloon was aspirated twice, then gently flushed with 20
mL of heparinized saline solution. Flushing was performed
to promote removal of larger debris that may not be re-
moved with the aspiration catheter into the external carotid
artery. This is similar in theory to the practice many sur-
geons use when performing CEA of initially flushing the
common carotid artery flow into the external carotid artery
before restoring flow to the ICA. After this, the GuardWire
balloon was deflated, flow was restored through the ICA,
and completion ipsilateral carotid bifurcation and intracra-
nial arteriograms were obtained.
Patients remained in the recovery room for 4 to 6
hours. If no hemodynamic instability occurred, they were
transferred to a standard hospital room. The next morning
a carotid duplex scan was obtained, and patients were
subsequently discharged to home with aspirin and clopi-
dogrel, 75 mg/d orally for 1 month. Carotid duplex scan-
ning was performed at 1 and 6 months, and yearly thereaf-
ter.
Patients underwent a neurologic examination per-
formed by the general surgery chief resident or vascular
fellow plus the surgical attending physician on postopera-
tive day 1 and at each clinic visit. Patients were not exam-
ined by an independent protocol neurologist. Any new
neurologic deficits were scored with the National Institutes
of Health (NIH) Stroke Scale.9 A major stroke was defined
as a new neurologic event that lasted longer than 24 hours,
with an increase in the NIH Stroke Scale greater than 3. A
minor stroke was defined as a new neurologic event that
lasted longer than 24 hours and was associated with an
increase in the NIH Stroke Scale of less than 3. A transient
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deficit that lasted less than 24 hours. A neurologic deficit
that developed during inflation of the GuardWire emboli-
zation protection balloon that completely resolved with
deflation of the balloon was not considered a TIA, but as
failure of embolization protection.
Myocardial infarction was defined as a troponin T level
greater than 0.03 ng/mL or an abnormal postoperative
electrocardiogram compared with preoperative findings
suggestive of myocardial infarction.
Recurrent stenosis was defined as stenosis greater than
50% with duplex ultrasound scanning criteria.
Data are presented as mean  SEM. Statistical analysis
was performed with analysis of variance (ANOVA) with
post hoc t test, with StatView Software (SAS Institute,
Cary, NC).
RESULTS
Patient demographic data. Seventy-four carotid ar-
teries were treated in 69 patients. Mean patient age was 72
 1 years, and 82% of patients were men. Comorbid
conditions included diabetes in 39% of patients, coronary
artery disease in 77% of patients, hypertension in 80% of
patients, creatinine concentration greater than 1.8 mg/dL
in 17% of patients, and active or recent tobacco use in 86%
of patients. A previous reconstruction for peripheral vascu-
lar or coronary artery disease had been performed in 51% of
patients. Medical management of this cohort of patients
included an angiotensin converting enzyme inhibitor in
69% and statins in 76%. Antiplatelet medications were used
in the perioperative period in all patients, including clopi-
dogrel in 95% and aspirin in 81%. Eleven percent of patients
received warfarin sodium (Coumadin) for reasons unre-
lated to carotid artery disease. Cardiac comorbidity was the
most common reason for selecting CAS over CEA, fol-
lowed by previous neck operations (Table I). Anatomic
high risk was present in 32% of patients, and medical high
risk in 53% of patients. Fifteen percent of patients who
underwent CAS had no associated increased risk factor for
CEA, and received treatment later in the series, on the basis
of clear patient preference.
Lesions. Primary atherosclerotic lesions were treated
in 81% of patients, recurrent stenosis after previous CEA in
18% of patients, and ICA dissection in 1% of patients. A
history of stroke was present in 15% of patients, and previ-
ous TIA in 23% of patients; 62% of patients had asymptom-
atic disease. Mean radiographic ICA stenosis in patients
with asymptomatic disease was 85%  2%, and in patients
with symptomatic disease was 78%  3%. In patients with-
out symptoms, 30% had a contralateral ICA occlusion or
stenosis greater than 80%, compared with 18% in patients
with symptoms (Fig).
Perioperative data. A femoral approach was used in
95% of patients, and a common carotid approach through a
limited neck incision with the patient under local anesthesia
in 5% of patients. Predilation with a 3-mm balloon beforestent placement but after balloon protection was performed
in 99% of patients. Self-expanding WallStents were placed
in 99% of patients, and Precise stents (Cordis) in 1% of
patients. The diameters of the stents used were 8 mm in
48% of procedures and 10 mm in 52% of procedures. A
5-mm angioplasty balloon was used for final angioplasty in
65% of patients, a 6-mm balloon in 34% of patients, and a
4-mm balloon in 1% of patients. Embolization protection
was established in 96% of patients. The PercuSurge Guard-
Wire system was used in 95% of patients, reversed internal
carotid artery flow in 1%, and no protection in 4%. The
procedures in which no cerebral protection was used were
to treat recurrent stenosis, early in our experience. Neuro-
logic changes occurred in 8% of patients when the Percu-
Surge GuardWire was inflated. Neurologic function recov-
ered promptly in all patients but one, once the balloon
protection device was deflated. In the one instance, com-
plete neurologic recovery required 30 minutes. This proce-
dure was also complicated by persistent bradycardia and
hypotension during this period. In the 8% of patients who
did not tolerate balloon inflation initially, all patients but
one tolerated subsequent inflation after systolic blood pres-
sure was increased by 30 to 40 mm Hg. Mean operative
time was 75  3 minutes; fluoroscopy time was 25  1
minutes; and mean volume of contrast agent (Visipaque)
used was 124  7 mL.
Early outcome. Technical success was achieved in
96% of procedures. The two causes of failure were intoler-
ance of GuardWire balloon protection device deployment
in one patient, and one episode of congestive heart failure
after thoracic flush aortography. The early complication
rate is shown in Table II. There were no deaths or major
strokes within 30 days. Minor stroke and TIA each oc-
curred in 1.3% of patients. The single patient with a minor
stroke had symptoms preoperatively, and normal results of
neurologic examination at 1-month follow-up. The single
TIA was manifested as a transient episode of expressive
aphasia in a patient with asymptomatic disease preopera-
tively. Patients with primary atherosclerosis had a com-
bined stroke and death rate of 2%; no stroke or death
occurred in patients with recurrent stenosis or dissection.
Additional complications occurred in 14% of patients (Ta-
ble III). Mean hospital stay was 1.4  0.2 days. Eighty
percent of patients were discharged to home in less than 24
hours. Ten percent of patients required a monitored bed
for monitoring of blood pressure or bradyarrhythmia.
Table I. High-risk categories
Category %
Anatomic
Hostile neck 25
Distal extent 6
Contralateral cranial nerve 1
Medical
Cardiac 49
Pulmonary 4
None 15
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There have been two cases of recurrent stenosis greater
than 50% at duplex scanning. No patient had stenosis
greater than 80% or required repeat intervention. The
number of deaths and of major and minor strokes has
remained unchanged since the 30-day follow-up.
Comparison with concurrent CEA. Although the
patients were not comparable, a comparison of our concur-
rent experience with CEA is provided for reference. During
the same period as this study of CAS, 266 carotid CEAs
were performed at our institution, with a neurologic event
rate of 0.8% (major stroke, 0.4%; no minor strokes; TIA,
0.4%) and a myocardial infarction rate of 3%.
DISCUSSION
CEA has achieved outstanding results in the treatment
of extracranial carotid occlusive disease. Multicenter ran-
domized trials comparing CEA with medical management
in patients with symptomatic disease include the North
American Symptomatic Carotid Endarterectomy Trial,1-3
the European Carotid Surgery Trial,4 and the Aspirin and
Carotid Endarterectomy trial,10 which have a combined
stroke and death rate of 2.3% in patients at good surgical
risk. The Asymptomatic Carotid Atherosclerosis Study sim-
ilarly showed a stroke and death rate of only 2.3% in
patients with asymptomatic disease with severe extracranial
carotid bifurcation occlusive disease.6
The use of CAS in patients with extracranial carotid
occlusive disease has been controversial. Early single-center
reports were encouraging.11 However, two subsequent
trials that directly compared CEA and CAS were stopped
early because of a significantly higher incidence of stroke in
the CAS group.12,13 The Carotid and Vertebral Artery
Transluminal Angioplasty Study was the first to show sim-
ilar stroke rates between CEA and CAS in a multicenter
trial.14 This trial was not thought representative of contem-
porary surgical results, however, because there was a stroke
rate of 9.9% in patients who underwent CEA. The SAP-
PHIRE Trial was a randomized multicenter trial that com-
pared the results of CEA with those of CAS in patients at
high risk with symptomatic and asymptomatic disease.7
This study was the first to demonstrate a better outcome in
the CAS group compared with the CEA group. These
investigators used an end point of multiple adverse events
that combined stroke, death, and myocardial infarction.
They observed a 30-day multiple adverse events rate of
5.8% in the CAS group, compared with 12.6% in the CEA
group.7,8 The major difference between the two treatment
Table II. Thirty-day operative outcome
Outcome %
Death 0
Major stroke 0
Minor stroke 1.3
Transient ischemic attack 1.3
Myocardial infarction 1.3groups was in the incidence of myocardial infarction; there
was no significant difference in major or minor stroke, or
death. These results have been maintained at 1-year follow-
up, at which time the multiple adverse events rate was 12%
in the CAS group and 20% in the CEA group.15 Whether
these results can be extrapolated to a patient population at
low risk is unknown. At present, Hobson16 is conducting
an NIH-sponsored trial (Carotid Revascularization and
Endarterectomy vs Stent Trial) that seeks to answer this
question.
The present study demonstrated a stroke and death rate
similar to that reported in previous CEA trials and lower
than that reported in the SAPPHIRE trial. There are several
explanations for the low stroke rate reported in our study.
First, our single-center experience is similar to that of
previous single-center reports, which tend to have lower
complication rates than those reported in multicenter trials.
Second, our patients were not examined by an independent
protocol neurologist, as in the SAPPHIRE trial, which may
have detected more subtle neurologic deficits. Third, the
cerebral protection device and stent system used in the
present study were different from those used in the SAP-
PHIRE trial. Fourth, we did not prospectively determine
cardiac enzyme levels in all patients, which could have
disclosed more subtle cardiac events. Last, a focused arte-
riographic approach was used in the performance of CAS in
this report. Only the target carotid artery was cannulated,
rather than performing four-vessel arteriography. This fo-
cused approach may have limited the wire and catheter
manipulation within the aortic arch, resulting in a lower
incidence of neurologic events.
There did not appear to be a significant learning curve
effect on the outcome of carotid stent placement by vascu-
lar surgeons in the present study. Previous investigators
have found a significant learning curve effect in the out-
come of CAS,17 and suggest that a minimum of 50 such
procedures must be performed to overcome the learning
curve effect. One possible explanation for the lack of a
learning curve effect in this report may be the endovascular
experience previously accumulated by the two vascular
surgeons (R.J.P., M.S.) who performed CAS procedures in
this study. Both surgeons had extensive experience with the
use of the embolization protection device and low-profile
systems in mesenteric and renal vascular beds before using
these devices in the carotid artery. In addition, both surgeons
had observed more than 15 CAS procedures at outside
institutions before beginning the carotid stent program.
Table III. Additional post-procedure complications*
Complication n
Bradyarrhythmia 3
Reperfusion syndrome (unilateral headache) 1
Groin hematoma 1
Blood pressure control for management of hypotension 3
Seizure 1
Groin infection 1
*Post-procedure (30 days) complications occurred in 14% of all patients.
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but two patients in this study. Patients who did not receive
embolization protection received treatment only for recur-
rent stenosis early in our experience. Ohki et al18 demon-
strated in an ex vivo model that atheroembolic particles are
generated during CAS from human carotid plaque speci-
mens. Although previous reports have demonstrated that the
use of embolization protection is safe, to date no randomized
report has demonstrated the superiority of embolization
protection in prevention of perioperative neurologic events
during CAS.19-23 A meta-analysis preformed by Kastrup et
al24 does support the use of cerebral protection devices.
These investigators have shown a reduction in neurologic
events, from 5.5% to 1.8%, after use of cerebral protection
devices. Similarly, Wholey et al,25 using a multicenter reg-
istry, demonstrated a stroke and death rate of 4.2% without
cerebral protection and 1.7% with protection. Despite the
lack of conclusive evidence suggesting the superiority of
embolization protection, the use of such devices has be-
come widespread as CAS has evolved.
In a randomized multicenter trial, use of the PercuSurge
GuardWire balloon embolization protection device resulted
in a 42% decrease in cardiac events after angioplasty of saphe-
nous vein graft lesions.26 Henry et al20 demonstrated a neu-
rologic event rate of 1.8% when this device was used in CAS.
The GuardWire has a low crossing profile, and was effective at
crossing all lesions in this report. The major drawback to this
device is that in 8% of patients in the present study neurologic
compromise developed with balloon inflation. All patients but
one recovered promptly after immediate balloon deflation. An
explanation for the delay in neurologic recovery in the one
patient was potentially the persistent bradycardia and hypo-
tension, which when resolved resulted in complete neurologic
recovery. This patient underwent successful repeat CAS the
next day, during which blood pressure was maintained at 30
to 40 mm hg higher than at the initial procedure. In general,
if a patient did not tolerate initial balloon occlusion of the ICA
with the GuardWire, the balloon was deflated, blood pressure
was elevated 30 to 40 mm Hg above baseline, and the balloon
was subsequently reinflated. All patients but one tolerated a
second attempt at balloon inflation.
The unknown incidence of stent-related recurrent ste-
nosis is an additional area of concern with CAS. The
incidence of recurrent stenosis in the present study at mean
follow-up of 6 months was 3%. This compares favorably
with previous CAS studies, which have shown an average
recurrent stenosis rate of 4.8%.25 As a result of the limited
follow-up in this group of patients, the durability of this
procedure will need further evaluation.
In conclusion, our initial experience with CAS, mainly
in patients at high surgical risk, was comparable with our
concurrent CEA experience, although follow-up was too
short to determine the ultimate durability of CAS. We
found that some patients have a very strong preference for
CAS over CEA, and may refuse an operative approach despite
its potential benefit. For this reason, vascular surgeons must
develop skills to perform and evaluate CAS, so that all appro-
priate treatment options are available to patients.REFERENCES
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